Maccabi Health Services' Kahn-Sagol-Maccabi (KSM) Research and Innovation Center has partnered with a California-based health tech startup to develop biomarkers for the early detection of colorectal, lung, pancreatic, and breast cancers, KSM announced Tuesday.
Follow Israel Hayom on Facebook, Twitter, and Instagram
KSM will be working with PrognomiQ, which is working to harness multi-omics data to transform the detection of cancers at an early stage.
The joint project will make use of Maccabi's Tipa Biobank, the largest biological bank in Israel. The Tipa Biobank is based on a nationwide population group, and includes more than 800,000 biological anonymized samples.
The Israeli data will be integrated with technology from PrognomiQ to create a biomarker platform to improve the early detection of these cancers as well as outcomes and care for cancer patients.
PrognomiQ's high-throughput approach allows for large-scale studies and the development of high sensitivity tests.
"Maccabi is paving the way for innovative research to better model a comprehensive, multi-dimensional, patient journey," said KSM head Dr. Tal Patalon.
"Interweaving the clinical course of diseases with the biological changes throughout time is the key to reaching a significant breakthrough in redefining diseases, and thus tailoring treatment and prevention specifically to each patient," Patalon added.
CEO of PrognomiQ Philip Ma called the collaboration with KSM "exciting."
"PrognomiQ's platform is unique in that it is taking a next-generation approach to broadly sample the proteomic, metabolome, epigenome, transcriptome and genome for biomarkers – and accomplishing this at large scale. The resulting multi-omics data sets provide unparalleled levels of biological insights and novel biological content that could lead to transformative new approaches to diagnostics and therapy development," Ma explained.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
